The most promising Alzheimer's treatments in recent years have focused on clearing the amyloid plaques that are a hallmark of the disease. For the team at Babylon Biosciences, that approach is akin to mopping up water after the pipes have burst. Their bet is earlier, and more fundamental: to rescue the essential cellular functions that fail long before plaques become visible, aiming to stop the cascade that leads to neurodegeneration.
Founded in 2023, the San Francisco-based biotech is in the earliest stages of discovering small-molecule therapeutics. What sets it apart is the sheer density of drug-hunting experience its founders have assembled. The team's collective resume reads like a history of modern pharmacology, credited with roles in bringing 51 FDA-approved medicines to patients [Babylon Biosciences, 2024]. Their prior discoveries include blockbusters like the blood pressure drug Lisinopril and the migraine therapy Nurtec ODT, the latter part of an $11.6 billion acquisition by Pfizer [Babylon Biosciences, 2024].
The veteran chemistry team as a strategic wedge
In biotech, where nine out of ten clinical candidates fail, a team that has repeatedly navigated the path from molecule to medicine is a rare competitive edge. Babylon's leadership is a who's who of medicinal chemistry and pharmacology, featuring three inductees into the ACS Medicinal Chemistry Hall of Fame [Babylon Biosciences, 2024]. The team includes CEO and founder Sacha Schermerhorn, whose background blends neural science with computer science [rocketreach.co, 2026]. Their stated mission is to deliver effective medicines by rescuing essential functions, a shift from the dominant 'clear the pathology' paradigm [Babylon Biosciences, 2024].
This experience is being applied to build a proprietary high-throughput screening platform, designed to rapidly test thousands of compound interactions [gosset.ai, 2026]. Babylon is collaborating with OpenAI and Sleuth Insights to fine-tune AI models with the goal of predicting clinical trial outcomes, potentially de-risking the long and expensive path to human studies [fiercebiotech.com, 2026].
The long road from discovery to clinic
The ambition is clear, but the path is long and fraught. Babylon is pre-clinical, with no disclosed candidates nearing an Investigational New Drug (IND) application. The company's funding is also undisclosed, though it has secured backing from investors including Mission BioCapital and Founders Fund [PRNewswire, 2026]. The primary risks are not about the team's pedigree but the inherent difficulty of the problem they've chosen.
- Biological complexity. The premise of rescuing 'essential functions' requires identifying the correct, druggable cellular targets very early in Alzheimer's pathogenesis.
- Clinical translation. A molecule that shows promise in a high-throughput screen or an AI model must still prove safe and effective in animals, and then in humans.
- Competitive landscape. Babylon enters a field crowded with well-funded giants and nimble startups, all chasing the same transformative treatment.
The company's stated plan is to license promising molecules for further development, a capital-efficient model that relies on proving value at the discovery stage [decodingbio.substack.com, 2026].
What success would mean for patients
For the estimated 6.7 million Americans living with Alzheimer's disease, the standard of care today offers limited symptom management but does nothing to slow the underlying progression of the condition. Babylon Biosciences is aiming for something different: an oral pill that could be taken earlier in the disease process, potentially preserving cognition and independence for years longer. The next twelve months will be about moving from thesis to tangible lead compounds, turning that veteran team's collective intuition into molecules worthy of the long journey ahead.